Rule 3.8A

Appendix 3E

Daily share buy-back notice (except minimum holding buy-back and selective buy-back)

Information and documents given to ASX become ASX's property and may be made public.

Nam	ne of entity		ABN/ARSN
Sig	ma Pharmaceuticals Limited	15 088 417 403	
We	(the entity) give ASX the following	ng information.	
Inf	formation about buy-back		
1	Type of buy-back	On-market buy-back	
2	Date Appendix 3C was given to ASX	13 September 2012 (Associated Append	lix 3D dated 4 O
		2013)	ix ob dated 4 of
	tal of all shares/units be ceptances have been recei	ought back, or in	relation to w
		ought back, or inved, before previous	relation to w n, previous day

Before previous	Previous day
day	

5 If buy-back is an on-market buy-back

Highest \$0.8525	price	paid:	Highest price paid: \$0.6150
Lowest	price	paid:	Lowest price paid: \$0.6000
\$0.5600	price	paiu.	Highest price allowed under rule 7.33: \$0.6153

How many shares/units may still be bought back?

6 If the company/trust has disclosed an intention to buy back a maximum number of shares/units – the remaining number of shares/units to be bought back

52,442,876			

Compliance statement

- 1. The company is in compliance with all Corporations Act requirements relevant to this buy-back.
- 2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.

or, for trusts only:

- 1. The trust is in compliance with all requirements of the Corporations Act as modified by Class Order 07/422, and of the trust's constitution, relevant to this buy-back.
- 2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.

Sign here:

Date: 16 December 2013

(Director/Company secretary)

Print name: SUE MORGAN

== == == ==